Vibration-controlled transient elastography: A practical approach to the noninvasive assessment of liver fibrosis

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 192-198

  Tapper, Elliot B ^a   Afdhal, Nezam H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cirrhosis; hepatitis C; liver disease; nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; INTERFERON; BIOLOGICAL MARKER;

CHRONIC HEPATITIS C; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; ELASTOGRAPHY; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; DISEASE COURSE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VIBRATION;

BIOMARKERS; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; VIBRATION;

EID: 84928558259     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000169     Document Type: Review

References (56)

1. Afdhal NH. Management of nonalcoholic fatty liver disease: A 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA 2012; 308:608-616.
2. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013; 178:38-45.
3. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143:1179-1187.
4. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
5. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med 2014; 370:1552-1553.
6. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. http://wwwhcvguidelinesorg. [Accessed 1 Jan 2015]
7. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500.
8. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13 369 examinations. Hepatology 2010; 51:828-835.
9. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014; 16:1-7.
10. de Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. J Hepatol 2014; 60:1026-1031.
11. Pang J, Pradhan F, Zimmer S, et al. The feasibility and reliability of transient elastography using Fibroscan1: A practice audit of 2335 examinations. Can J Gastroenterol Hepatol 2014; 28:143-149.
12. Tapper EB, Castera L, Afdhal NH. FibroScan (vibration controlled transient elastography): where does it stand in the US practice. Clin Gastroenterol Hepatol 2015; 13:27-36.
13. Wong VW-S, Vergniol J, Wong GL-H, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107:1862-1871.
14. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55:199-208.
15. Arena U, Lupsor Platon M, Stasi C, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013; 58:65-72.
16. Lebray P, Varnous S, Charlotte F, et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008; 48:2089-12089.
17. de Lédinghen V, Wong VW-S, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan1. J Hepatol 2012; 56:833-839.
18. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48:1718-1723.
19. Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2012; 10:932-937; e931.
20. Van Gossum A, Pironi L, Messing B, et al. Transient elastography (FibroScan) is not correlated with liver fibrosis but with cholestasis in patients with longterm home parenteral nutrition. J Parenter Enteral Nutr 2014. [Epub ahead of print]
21. Chung RT, Baumert TF. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014; 370:1576-1578.
22. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost? Science 2014; 345:141-142.
23. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60:832-843.
24. Hagan L, Yang Z, Ehteshami M, Schinazi R. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013; 20:847-857.
25. Afdhal NH, Bacon BR, Patel K, et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: A US multicenter study. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
26. Zarski J-P, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56:55-62.
27. Vergniol J, Boursier J, Coutzac C, et al. The evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology 2014; 60:65-76.
28. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTestTM) and transient elastography (FibroScan1). J Hepatol 2014; 60:706-714.
29. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
30. Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012; 32:612-621.
31. Klibansky D, Mehta S, Curry M, et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat 2012; 19:e184-e193.
32. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55:2005-2023.
33. Festi D, Schiumerini R, Marzi L, et al. Review article: the diagnosis of nonalcoholic fatty liver disease-availability and accuracy of noninvasive methods. Aliment Pharmacol Ther 2013; 37:392-400.
34. Younossi ZM, Zheng L, Stepanova M, et al. Trends in outpatient resource utilizations and outcomes for medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol 2015; 49:222-227.
35. Tapper EB, Krajewski K, Lai M, et al. Simple noninvasive biomarkers of advanced fibrosis in the evaluation of nonalcoholic fatty liver disease. Gastroenterol Rep 2014; 2:276-280.
36. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2014. [Epub ahead of print]
37. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan1: validation in chronic hepatitis C. J Viral Hepat 2012; 19:244-253.
38. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29:1149-1158.
39. Castera L. Hepatitis B: Are noninvasive markers of liver fibrosis reliable? Liver Int 2014; 34 (Suppl 1):91-96.
40. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142:1293-1302.
41. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: A meta-analysis. PloS One 2012; 7:e44930.
42. Fung J, Lai C-L, Chan S-C, et al. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. Am J Gastroenterol 2010; 105:1116-1122.
43. Kim JH, Kim MN, Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2014. [Epub ahead of print]
44. Oliveri F, Coco B, Ciccorossi P, et al. Liver stiffness in the hepatitis B virus carrier: A noninvasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008; 14:6154-6162.
45. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan). J Hepatol 2014; 61:994-1003.
46. Trembling P, Lampertico P, Parkes J, et al. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014; 21:430-438.
47. Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: A systematic review and meta-analysis of diagnostic test accuracy. PloS One 2014; 9:e100182.
48. Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4:936-962.
49. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
50. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43:1118-1124.
51. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastographybased assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56:198-208.
52. Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146:970-979; e976..
53. Czaja A. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014; 39:385-406.
54. Adhoute X, Foucher J, Laharie D, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: A prospective study. Gastroentérol Clin Biol 2008; 32:180-187.
55. Legros L, Bardou-Jacquet E, Latournerie M, et al. Noninvasive assessment of liver fibrosis in c282y homozygous hfe hemochromatosis. Liver Int 2014. [Epub ahead of print]
56. de Lédinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45:443-450.